Seizure disorder (epilepsy). A specific cannabidiol product (Epidiolex, GW Pharmaceuticals) has been shown to reduce seizures in adults and children with various conditions that are linked with seizures. This product is a prescription drug for treating seizures caused by Dravet syndrome or Lennox-Gastaut syndrome. It has also been shown to reduce seizures in people with tuberous sclerosis complex, Sturge-Weber syndrome, febrile infection-related epilepsy syndrome (FIRES), and specific genetic disorders that cause epileptic encephalopathy. But it's not approved for treating these other types of seizures.
The good news is that numerous states have enacted legislation that allows for the use of CBD. Just four states (Idaho, South Dakota, Nebraska, and Kansas) forbid any access to marijuana. Ten states and Washington, D.C., currently allow for both medical and recreational use of cannabis, including CBD products. The other 36 states allow for the use of medical cannabis in some form, though some of these relegate this to CBD oil only.
However, when cannabinoids are taken externally, it’s difficult to distinguish between the clinically desirable effects and the therapeutically undesirable effects of various phytocannabinoids. This is because cannabinoid receptors send a variety of signals that often interconnect to coordinate the body’s functions, so it’s hard to tell them apart.
We’ve established the fact that naturally occurring CBD is the same CBD regardless of the plant it came from. However, CBD and CBD oil are not in fact the same thing. As we’ve seen above, CBD is a chemical compound with sharply defined characteristics, while CBD oil is a mixture of various natural substances as they are derived from the plant of cannabis.
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side-effect profile.
Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids. Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. As defined by U.S. federal law, non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis. Certain standards are required for legal growing, cultivating, and producing the hemp plant. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%. cbd oil
In the United States, the cannabidiol drug Epidiolex was approved by the Food and Drug Administration in 2018 for treatment of two epilepsy disorders. Since cannabis is a Schedule I controlled substance in the United States, other CBD formulations remain illegal to prescribe for medical use or to use as an ingredient in foods or dietary supplements. cannabidiol oil